Zobrazeno 1 - 10
of 220
pro vyhledávání: ''
Autor:
Atsushi Naganuma, Takaaki Tanaka, Atsushi Hiraoka, Satoshi Yasuda, Kazuya Kariyama, Noritomo Shimada, Shinichiro Nakamura, Satoru Kakizaki, Michitaka Imai, Koichi Takaguchi, Takuya Nagano, Toshifumi Tada, Akemi Tsutsui, Takashi Kumada, Takeshi Hatanaka, Kazuhiro Nouso, Toru Ishikawa, Kunihiko Tsuji, Hidenori Toyoda, Hiroshi Shibata, Ei Itobayashi
Publikováno v:
Oncology
Background/Aim: With the development of systemic treatment methods for unresectable hepatocellular carcinoma (uHCC), the concept of unsuitable for transcatheter arterial chemoembolization (TACE) has become important. This study aimed to establish a s
Autor:
Kotaro Yamashita, Makoto Yamasaki, Hidetoshi Eguchi, Yuichiro Doki, Tomoki Makino, Kiyokazu Nakajima, Takuro Saito, Norihiro Matsuura, Yukinori Kurokawa, Tsuyoshi Takahashi, Koji Tanaka, Yutaka Kimura, Masaaki Motoori, Kazuyoshi Yamamoto
Publikováno v:
Oncology. 99:547-554
Purpose: Esophageal cancer patients may simultaneously have resectable esophageal cancer and undiagnosable incidental minute solid pulmonary nodules. While the latter is rarely metastatic, only a few studies have reported on the outcomes of such nodu
Autor:
Young Suk Park, Jeeyun Lee, Hyera Kim, Seonggyu Byeon, Jung Yong Hong, Se Hoon Park, Kee-Taek Jang, Won Ki Kang, Joon Oh Park, Seung Tae Kim, Ho Yeong Lim, Jinchul Kim
Publikováno v:
Oncology. 99:365-372
Background: Biliary tract cancer (BTC) is associated with poor prognosis because of its aggressive and heterogeneous nature. Programmed death ligand 1 (PD-L1) has been considered a novel biomarker for prognosis and response of immune checkpoint inhib
Autor:
Savtaj S. Brar, Carol Jane Swallow, Charles Henry Lim, Hao-Wen Sim, Jennifer J. Knox, Bryan A. Chan, Akina Natori, James Brierley, Osvaldo Espin-Garcia, Rebecca Wong, Jolie Ringash, Eric Chen, Elena Elimova, Sara Hafezi-Bakhtiari, John Kim, Raymond Woo-Jun Jang, Di Maria Jiang, Geoffrey Liu, Patrik Rogalla, Gail Darling, Stephanie Moignard
Publikováno v:
Oncology. 99:49-56
Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alte
Autor:
Hitomi Sezaki, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Fumitaka Suzuki, Tetsuya Hosaka, Yoshiyuki Suzuki, Masahiro Kobayashi, Yusuke Kawamura, Satoshi Saitoh, Shunichiro Fujiyama, Hiromitsu Kumada, Norio Akuta
Publikováno v:
Oncology. 99:114-123
Introduction: It remains unclear whether TERT promoter mutation (TERT C228T) in serum cell-free DNA (cfDNA) is useful for the diagnosis of hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD). Methods: In this retr
Autor:
Yu-Feng Tian, Pei-Ling Hsieh, Ching-Chieh Yang, Chia-Lin Chou, Yow-Ling Shiue, Sung-Wei Lee, Wan-Shan Li, Cheng-Yi Lin
Publikováno v:
Oncology. 98:549-557
Background/Aim: A great proportion of patients with rectal cancer initially present with locally advanced disease and can potentially benefit from neoadjuvant concurrent chemoradiotherapy (CCRT) for downstaging before surgery. However, risk and clini
Autor:
Yoshinari Asaoka, Tetsuo Ushiku, Jun Kinoshita, Yoshiumi Ouchi, Masamichi Koike, Ryosuke Tateishi, Junji Shibahara, Masashi Fukayama, Akimasa Hayashi, Kazuhiko Koike, Shuichiro Shiina
Publikováno v:
Oncology. 98:186-194
Background:The clinical course of hepatocellular carcinoma (HCC) is complicated, because it often recurs and shows multiple lesions, some of which progress to a more malignant form, shortening the life of the patient. The hepatocyte growth factor rec
Autor:
Chikage Iguchi, Eiichi Shiba, Noriko Fujita, Keiko Inakami, Hitoshi Yamamoto, Tsutomu Kasugai, Takashi Nomura, Tetsu Yanagisawa, Yukie Enomoto, Toyokazu Aono
Publikováno v:
Oncology. 98:35-41
Background: It is unclear for whom new anti-human epidermal growth factor receptor 2 (anti-HER2) agents, such as pertuzumab and T-DM1, should be considered. We investigated prognostic factors before neoadjuvant chemotherapy (NAC) among HER2-positive
Autor:
Kohei Tajima, Hisao Imai, Kyoichi Kaira, Ryoichi Onozato, Ken Masubuchi, Sayaka Kawashima, Koichi Minato
Publikováno v:
Oncology. 100(2)
Introduction: In stage I–III non-small cell lung cancer (NSCLC), which is considered operable, surgical resection is the most efficacious treatment and is considered to provide a cure. However, after complete surgical resection, approximately 50% o
Autor:
Angeline Ginzac, Ioana Molnar, Xavier Durando, Pierre-François Montoriol, Cécile Mione, Hakim Mahammedi, Tressie Herrmann
Publikováno v:
Oncology
Oncology, Karger, 2022, ⟨10.1159/000520833⟩
Oncology, Karger, 2022, ⟨10.1159/000520833⟩
Introduction: The advent of immune checkpoint inhibitors (ICIs) such as nivolumab has enabled outcomes for metastatic renal cell carcinoma (mRCC) to be improved. However, only around 25% of patients respond to these therapies without being able to fo